ArticleCase reports in hematology2026
Case of Myelodysplastic Syndrome 15 Years After Kidney Transplantation Under Long-Term Immunosuppression.
Article in Case reports in hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case of Myelodysplastic Syndrome 15 Years After Kidney Transplantation Under Long-Term Immunosuppression.Case reports in hematology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In solid organ transplant recipients receiving long-term immunosuppression, persistent or progressive pancytopenia is often initially attributed to infections or drug toxicity, thereby potentially delaying the recognition of clonal myeloid disorders and germline predispositions. We report the case of a kidney transplant recipient who had predominantly maintained tacrolimus-based immunosuppression and presented with progressive pancytopenia and marked reticulocytopenia. Bone marrow evaluation revealed severe hypocellularity with suppression of granulopoiesis and erythropoiesis, as well as prominent dysmegakaryopoiesis. Flow cytometry showed a small population of immunophenotypically aberrant myeloid blasts, supporting a diagnosis of hypocellular myelodysplastic syndrome. Myeloid gene next-generation sequencing detected a FANCA missense variant (c.3630C > A; p.F1210L; variant allele frequency 47.2%), prompting consideration of germline-associated marrow failure or genetic susceptibility and the need for confirmatory testing in nonhematopoietic tissues. During hospitalization, the patient developed severe opportunistic infections that rapidly progressed to respiratory failure and hemodynamic instability. This case highlights the need for early marrow evaluation and genetic risk stratification in transplant recipients with unexplained cytopenia and for the dynamic balancing of hematopoietic rescue against preservation of allograft function to reduce diagnostic delays and subsequent complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.